多基因背景影响GCK-MODY临床表现与血糖变异性
研究分析897例临床转诊的GCK-MODY患者、7645名非糖尿病对照、4773例2型糖尿病患者和601例HNF1A-MODY患者,并评估158例UK Biobank中临床未选择的GCK变异携带者。结果显示临床转诊GCK-MODY患者存在HbA1c、空腹血糖和2型糖尿病多基因富集,且HbA1c多基因评分与实测HbA1c相关,高五分位者超糖尿病诊断阈值风险增加3-6倍。
要点
- 临床转诊GCK-MODY患者HbA1c、空腹血糖和2型糖尿病PGS高于非糖尿病对照。
- GCK-MODY与HNF1A-MODY多基因富集模式不同,仅2型糖尿病PGS在HNF1A-MODY中独立贡献。
- GCK-MODY患者HbA1c PGS最高五分位者超糖尿病诊断阈值风险增加3-6倍。
核心结论
- 多基因背景与GCK变异交互作用修饰GCK-MODY的血糖表达并影响临床诊断。
- GCK-MODY多基因贡献模式不同于HNF1A-MODY,体现病因特异性交互。
研究设计与样本
- 分析897例临床转诊GCK-MODY患者九项糖尿病相关性状的PGS。
- 对照包括7645名非糖尿病参与者、4773例2型糖尿病患者和601例HNF1A-MODY患者。
- 另评估158例UK Biobank中临床未选择的GCK变异携带者。
主要发现
- 临床转诊GCK-MODY患者HbA1c、空腹血糖和2型糖尿病PGS较非糖尿病对照高0.16-0.33 SD(均p<0.003)。
- GCK-MODY患者HbA1c和空腹血糖PGS高于2型糖尿病和HNF1A-MODY组,而2型糖尿病PGS较低。
- HNF1A-MODY中仅2型糖尿病PGS独立贡献(0.33 SD,p<1×10⁻²⁷)。
- 临床未选择GCK变异携带者中未见多基因富集。
- GCK携带者HbA1c PGS与实测HbA1c相关(临床转诊β=0.97,临床未选择β=0.91,均p<0.009)。
临床怎么用
- 解读GCK-MODY血糖表型时需考虑多基因背景对HbA1c和空腹血糖的影响。
- GCK-MODY患者HbA1c PGS较高时需警惕其超过糖尿病诊断阈值的风险。
- 多基因背景与GCK变异的交互模式有助于区分GCK-MODY与HNF1A-MODY。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: GCK-MODY (glucokinase MODY) causes lifelong, mild hyperglycaemia with high penetrance. Variation in glycaemic phenotype among carriers remains unexplained. We hypothesised that polygenic background contributes to this variability and that this influence differs from that of HNF1A-MODY. METHODS: To test whether polygenic background contributes to the GCK-MODY clinical phenotype, we analysed polygenic risk scores (PGS) for nine diabetes-related traits in 897 clinically referred individuals with GCK-MODY. We compared these to 7645 non-diabetic control participants, 4773 participants with type 2 diabetes and 601 participants with HNF1A-MODY and assessed associations between PGS and glycaemic measures. Additionally, we evaluated 158 clinically unselected GCK variant carriers from the UK Biobank to examine polygenic effects independent of clinical referral. RESULTS: We observed independent polygenic enrichment for HbA1c (including both glycaemic and non-glycaemic components), fasting glucose and type 2 diabetes in clinically referred GCK-MODY individuals compared with non-diabetes controls (0.16-0.33 SD higher, all p<0.003), but not for type 1 diabetes. Importantly, HbA1c and fasting glucose PGSs were higher than in both type 2 diabetes and HNF1A-MODY groups, whereas type 2 diabetes PGS was lower. GCK-MODY and HNF1A-MODY showed distinct patterns of polygenic enrichment, with only the type 2 diabetes PGS contributing independently in HNF1A-MODY (0.33 SD, p<1 × 10⁻27). By contrast, no polygenic enrichment was seen in GCK pathogenic variant carriers from a clinically unselected population-based cohort. In both settings, HbA1c PGS were associated with measured HbA1c levels in GCK carriers (clinically referred: β=0.97, clinically unselected: β=0.91, both p<0.009), with effect sizes similar to those in non-carriers. GCK-MODY cases in the top HbA1c quintile had a 3-to-6-fold risk of exceeding the diabetes diagnostic HbA1c threshold (≥48 mmol/mol) in clinically selected and clinically unselected cohort respectively. CONCLUSIONS/INTERPRETATION: Our findings suggest that polygenic background and GCK variants interact to modify the glycaemic expression of GCK-MODY, influencing clinical diagnosis despite high penetrance. The pattern of polygenic contribution differs from that of HNF1A-MODY, highlighting the aetiology specific interaction. Our study highlights the importance of integrating both monogenic and polygenic factors to better understand phenotypic variability in monogenic diseases.
引用
- Murray Leech J, Arni AM, Chundru VK, et al. Polygenic background contributes to GCK-MODY clinical presentation and glycaemic variability. Diabetologia. 2026. PMID: 41848901. doi:10.1007/s00125-026-06712-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。